SURMOUNT-MMO GLP1-RA for weight loss in patients without diabetes and increased cardiovascular risk. Enrollment to begin soon.
Evolve-MI (Amgen) Phase IV • Evolucumab + statin vs standard of care early after MI (STEMI/ACS NSTEMI). Open label
PREVAIL (New Amsterdam Pharma) Phase III • Obicetrapib (CETP inhibitor) vs placebo PO Daily for patients with ASCVD and LDL chol >70
Oceans(a) (Amgen) Phase III • Olparsiran vs standard of care early after treatment of Lipoprotein a (Lp(a)) in patgients with h/o MI or high risk patietns after PCI. Double blind placebo controlled study.
VICTORION-INCEPTION (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care for patients with recent acute coronary syndrome
ORION-4 (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo; examining outcomes in subjects with heart attack or stroke
VICTORION-INITIATE (Novartis)- Phase III • (*no longer enrolling*) Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care; assessing an “inclisiran-first” strategy in an ASCVD population
VESALIUS-CV (Amgen)- Phase III (*no longer enrolling*) • Evolocumab (monoclonal antibody, PCSK9 inhibitor) vs. Placebo; assessing the effect of evolocumab on major cardiovascular events in adults with prior heart attack or stroke
OCEANIC-AF (Bayer) Phase III • Asundexian (FXIa inhibitor) vs. apixaban for patients with atrial fibrillation.
RAPID (Milestone)- Phase III • Etripamil (novel intra-nasal verapamil analogue) vs. Placebo for the rapid termination of PSVT episodes
AZALEA (Anthos/TIMI)- Phase II (*no longer enrolling*) • Abelacimab (subcutaneous monoclonal antibody) vs. Rivaroxaban; assessing the bleeding profile of abelacimab in patients with AF with moderate-to-high risk of stroke o Paroxysmal Supraventricular Tachycardia
Expand TAVR II (Medtronic) • Evolut™ PRO and Evolut™ PRO+ Device in patients with moderate AS and Class II-III heart failure.
Optimize PRO (Medtronic) • (*no longer enrolling*) Evolut™ PRO and Evolut™ PRO+ Device Trial examining valve performance & procedural outcomes associated with an “optimized” TAVR (transcatheter aortic valve replacement) care pathway & post-TAVR conduction disturbance pathway
EXPAND G4 (Abbott) (*no longer enrolling*) • MitraClip device trial evaluating outcomes & characterizing trends in patient selection
DAPA ACT HF (AstraZeneca) • Phase IV o Dapagliflozin vs. Placebo; examining outcomes from in-hospital initiation in acute heart failure o Heart Failure with Preserved Ejection Fraction & Obesity
GPID SUMMIT (Eli Lilly)- Phase III • Tirzepatide (GIP & GLP-1 agonist) vs. Placebo in obese patients with chronic heart failure with preserved ejection fraction
RADIANCE II (Recor) • Paradise System device trial examining the effects of ultrasound renal denervation in subjects with medication-resistant hypertension
Copyright © 2022 FuturePulse Thomas Nero MD- All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.